Literature DB >> 17502832

MRP2 haplotypes confer differential susceptibility to toxic liver injury.

Ji Ha Choi1, Byung Min Ahn, Jihyun Yi, Ji Hyun Lee, Jeong Ho Lee, Soon Woo Nam, Chae Yoon Chon, Kwang-Hyub Han, Sang Hoon Ahn, In-Jin Jang, Joo-Youn Cho, Yousin Suh, Mi-Ook Cho, Jong-Eun Lee, Kyung Hwan Kim, Min Goo Lee.   

Abstract

OBJECTIVES: Multidrug resistance protein 2 (MRP2, ABCC2) plays an important role in the biliary clearance of a wide variety of endogenous and exogenous toxic compounds. Therefore, polymorphisms and mutations in the MRP2 gene may affect individual susceptibility to hepatotoxic reactions.
METHODS: Associations between genetic variations of MRP2 and toxic hepatitis were investigated using integrated population genetic analysis and functional molecular studies.
RESULTS: Using a gene scanning method, 12 polymorphisms and mutations were found in the MRP2 gene in a Korean population. Individual variation at these sites was analyzed by conventional DNA screening in 110 control subjects and 94 patients with toxic hepatitis induced mostly by herbal remedies. When haplotypes were identified, over 85% of haploid genes belonged to the five most common haplotypes. Among these, a haplotype containing the g.-1774delG polymorphism showed a strong association with cholestatic or mixed-type hepatitis, and a haplotype containing the g.-1549G>A, g.-24C>T, c.334-49C>T, and c.3972C>T variations was associated with hepatocellular-type hepatitis. A comprehensive functional study of these sites revealed that genetic variations in the promoter of this gene are primarily responsible for the susceptibility to toxic liver injuries. The g.-1774delG variation and the combined variation of g.-1549G>A and g.-24C>T decreased MRP2 promoter activity by 36 and 39%, respectively. In addition, the promoter carrying the g.-1774delG allele showed a defect in the bile acid-induced induction of promoter activity.
CONCLUSIONS: These results suggest that genetic variations of MRP2 are an important predisposing factor for herbal-induced or drug-induced toxic liver injuries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502832     DOI: 10.1097/01.fpc.0000236337.41799.b3

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  27 in total

1.  Laparoscopic treatment of hepatic cysts located in the posterosuperior segments of the liver.

Authors:  Doo-Ho Lee; Jai Young Cho; Ho-Seong Han; Yoo-Seok Yoon; Dae Wook Hwang; Kyuwhan Jung; Young Ki Kim; Hong Kyung Shin; Woohyung Lee
Journal:  Ann Surg Treat Res       Date:  2014-04-24       Impact factor: 1.859

Review 2.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Authors:  Daniel W Nebert; Ge Zhang; Elliot S Vesell
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 3.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

4.  Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).

Authors:  Vandana Megaraj; Tianyong Zhao; Christian M Paumi; Phillip M Gerk; Richard B Kim; Mary Vore
Journal:  Pharmacogenet Genomics       Date:  2011-08       Impact factor: 2.089

Review 5.  Genetic determinants of hepatic steatosis in man.

Authors:  Amanda J Hooper; Leon A Adams; John R Burnett
Journal:  J Lipid Res       Date:  2011-01-18       Impact factor: 5.922

6.  Association of CYP2C9*2 with bosentan-induced liver injury.

Authors:  S M Markova; T De Marco; N Bendjilali; E A Kobashigawa; J Mefford; J Sodhi; H Le; C Zhang; J Halladay; A E Rettie; C Khojasteh; D McGlothlin; A H B Wu; W-C Hsueh; J S Witte; J B Schwartz; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2013-07-17       Impact factor: 6.875

7.  The 5'-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation.

Authors:  Yuanyuan Zhang; Tianyong Zhao; Wei Li; Mary Vore
Journal:  Mol Pharmacol       Date:  2009-11-04       Impact factor: 4.436

Review 8.  Pharmacogenomics: a tool for improving cancer chemotherapy.

Authors:  Mariano Monzó; Alfons Navarro; Gerardo Ferrer; Rosa Artells
Journal:  Clin Transl Oncol       Date:  2008-10       Impact factor: 3.405

Review 9.  Pharmacogenomics of adverse drug reactions.

Authors:  Ann K Daly
Journal:  Genome Med       Date:  2013-01-29       Impact factor: 11.117

10.  Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report.

Authors:  Rajanshu Verma; Radhika Dhamija; Donald H Batts; Stephen C Ross; Mark E Loehrke
Journal:  Cases J       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.